PCM
LFCR icon

Penn Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Penn Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-207,253
Closed -$1.65M – 201
2020
Q2 		$1.65M Sell
207,253
-211,724
-51% -$2.18M 0.21% 157
2020
Q1 		$3.64M Sell
418,977
-110,022
-21% -$1.14M 0.6% 67
2019
Q4 		$5.98M Buy
528,999
+71,366
+16% +$759K 0.63% 55
2019
Q3 		$4.97M Buy
457,633
+60,440
+15% +$658K 0.52% 72
2019
Q2 		$3.72M Buy
397,193
+125,662
+46% +$1.27M 0.37% 103
2019
Q1 		$3.33M Buy
+271,531
New +$3.31M 0.32% 102

Other funds holding LFCR

LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return

Penn Capital Management's LFCR Position: Q3 2020 in Review

Penn Capital Management sold out of Lifecore Biomedical (LFCR) in Q3 2020, closing a stake of 207,253 shares — an estimated $1.65M sold.

Penn Capital Management first reported a position in LFCR in Q1 2019 and held it in 6 quarters. The position peaked at $5.98M in Q4 2019. 96 funds tracked by Wall St. Rank hold LFCR as of Q3 2020.

  • Penn Capital Management reported no remaining Lifecore Biomedical position as of Q3 2020 after selling out during the quarter.
  • Penn Capital Management sold 207,253 Lifecore Biomedical shares in Q3 2020, an estimated $1.65M.
  • Penn Capital Management first reported a position in Lifecore Biomedical in Q1 2019 and held it in 6 quarters.
  • Penn Capital Management's Lifecore Biomedical position peaked at $5.98M in Q4 2019.
  • 96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2020.

Based on Penn Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.